AUTERI, GIUSEPPE
 Distribuzione geografica
Continente #
NA - Nord America 378
EU - Europa 127
AS - Asia 126
SA - Sud America 35
AF - Africa 26
OC - Oceania 1
Totale 693
Nazione #
US - Stati Uniti d'America 369
SG - Singapore 87
IE - Irlanda 42
BR - Brasile 32
IT - Italia 30
CN - Cina 27
BE - Belgio 17
SN - Senegal 13
RU - Federazione Russa 8
CA - Canada 6
CI - Costa d'Avorio 6
FI - Finlandia 6
KR - Corea 5
CH - Svizzera 4
NG - Nigeria 4
AT - Austria 3
ES - Italia 3
GB - Regno Unito 3
UA - Ucraina 3
AR - Argentina 2
DE - Germania 2
IN - India 2
MA - Marocco 2
MX - Messico 2
NL - Olanda 2
PL - Polonia 2
AU - Australia 1
BD - Bangladesh 1
FR - Francia 1
IQ - Iraq 1
JM - Giamaica 1
JO - Giordania 1
KE - Kenya 1
LT - Lituania 1
PK - Pakistan 1
TR - Turchia 1
UY - Uruguay 1
Totale 693
Città #
Santa Clara 94
Houston 70
Singapore 65
Dublin 38
Chandler 31
Chicago 21
Brussels 17
Ashburn 16
Boardman 14
Civitanova Marche 13
Dakar 13
Cambridge 11
Lawrence 11
Andover 10
Des Moines 9
Hefei 8
Abidjan 6
Seoul 5
Turku 5
Abuja 4
Hebei 4
Saint Petersburg 4
Ann Arbor 3
Nanjing 3
Toronto 3
Boston 2
Brooklyn 2
Los Angeles 2
Messina 2
Mexico City 2
Montreal 2
Munich 2
Redwood City 2
Sassuolo 2
Seattle 2
São Paulo 2
Washington 2
Wilmington 2
Aci Sant'Antonio 1
Agadir 1
Amman 1
Amsterdam 1
Aracati 1
Atlanta 1
Baoding 1
Beijing 1
Belo Horizonte 1
Brejo Santo 1
Cabo Frio 1
Cametá 1
Campo Grande 1
Charqueada 1
Columbus 1
Cranford 1
Dearborn 1
Eusébio 1
Fazenda Nova 1
Fresno 1
Gravatá 1
Guanhães 1
Guareí 1
Guaíra 1
Hangzhou 1
Itaquaquecetuba 1
Itu 1
Jacksonville 1
Jandira 1
Jiaxing 1
Jundiaí 1
Kunming 1
Lagoa do Itaenga 1
Lahore 1
Lappeenranta 1
Leopoldina 1
London 1
Loveland 1
Mairiporã 1
Manchester 1
Melbourne 1
Merlo 1
Milan 1
Montevideo 1
Moscow 1
Nairobi 1
Nanuque 1
Naples 1
Nova Iguaçu 1
Oriximiná Municipality 1
Ottawa 1
Passo Fundo 1
Piraju 1
Portmore 1
Praia Grande 1
Providence 1
Rajahmundry 1
Royal Oak 1
San Jose 1
Santo Antônio de Pádua 1
Secaucus 1
Shanghai 1
Totale 566
Nome #
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 121
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data 54
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome 51
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 51
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study 50
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 50
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib 50
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients 49
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome 48
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis 47
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis 44
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients 42
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib 39
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study 20
Totale 716
Categoria #
all - tutte 2.964
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.964


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202117 0 0 0 3 6 1 3 0 2 1 1 0
2021/202267 3 10 0 0 12 2 11 0 1 7 1 20
2022/2023117 11 0 7 1 9 23 2 26 23 0 7 8
2023/202486 6 30 4 4 4 13 7 1 0 1 10 6
2024/2025301 4 37 14 17 79 39 6 3 20 23 38 21
2025/202637 37 0 0 0 0 0 0 0 0 0 0 0
Totale 716